Reuters logo
3 个月前
BRIEF-Abeona Therapeutics receives pediatric disease designation for EB-101 gene therapy product for patients with Epidermolysis Bullosa
2017年5月30日 / 中午12点27分 / 3 个月前

BRIEF-Abeona Therapeutics receives pediatric disease designation for EB-101 gene therapy product for patients with Epidermolysis Bullosa

May 30 (Reuters) - Abeona Therapeutics Inc:

* Abeona Therapeutics receives rare pediatric disease designation for eb-101 gene therapy product for patients with Epidermolysis Bullosa Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below